Lexeo Therapeutics, Inc.
LXEO
$5.09
-$0.41-7.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 38.16% | 19.31% | 31.22% | -22.91% | -50.61% |
| Total Depreciation and Amortization | 8.98% | 3.26% | 4.13% | 2.82% | 5.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -26.85% | -22.47% | -28.47% | -110.01% | 59.12% |
| Change in Net Operating Assets | -162.51% | 62.56% | -269.35% | 40.56% | 67.91% |
| Cash from Operations | 2.63% | 29.11% | -65.94% | -35.07% | -46.07% |
| Capital Expenditure | -- | -- | -248.19% | 49.30% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 76.25% | -8.66% | -- | -781,220.00% | 195,100.00% |
| Cash from Investing | 76.03% | -8.66% | 42,281.93% | -17,869.72% | 8,182.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 23.90% | -45.69% | 25.23% | -64.86% | -45.87% |
| Issuance of Common Stock | 1,428.24% | 668,482.61% | 246.15% | 1,100.29% | -99.81% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -10.02% | -- |
| Cash from Financing | 22,190.91% | 148,318.56% | 172.22% | 24,972.16% | -99.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 243.62% | 118.04% | 130.71% | 132.71% | -108.30% |